Last reviewed · How we verify
Sitaxsentan
At a glance
| Generic name | Sitaxsentan |
|---|---|
| Also known as | Sitaxsentan-Thelin, Thelin, Sitaxentan |
| Sponsor | Pfizer |
| Target | Endothelin B receptor, Endothelin-1 receptor, Endothelin-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Approved indications
- Pulmonary arterial hypertension
Common side effects
Key clinical trials
- A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan P (Phase 1)
- A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects (Phase 1)
- Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin (N/A)
- A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension (Phase 3)
- A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE (Phase 2)
- Proteolytic Enzyme Induction Within the Human Myocardial Interstitium (NA)
- Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man (EARLY/Phase 1)
- Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan. (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sitaxsentan CI brief — competitive landscape report
- Sitaxsentan updates RSS · CI watch RSS
- Pfizer portfolio CI